Helius Medical Technologies to Present at the Virtual Summer Summit on June 9th

Rhea-AI Summary

Helius Medical Technologies (Nasdaq: HSDT) announced its participation in the Virtual Summer Summit, scheduled from June 9th-12th, 2020. Management will present on June 9th at 4:30 p.m. ET. A live audio webcast will be available on the company's investor relations website, with an archived replay after the conference.

Helius focuses on neurological wellness, developing non-invasive technologies. Its first product, the Portable Neuromodulation Stimulator (PoNS™), targets gait deficits from neurological conditions.

NEWTOWN, Pa., June 05, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the Virtual Summer Summit, which is being held from June 9th-12th. Management will present on Tuesday, June 9th at 4:30 p.m. Eastern Time.

A live audio webcast of the presentation will be provided under the ‘Events’ section of the Helius Medical Technologies investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events. An archive of the webcast will be available for replay following the conference.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS™). For more information, visit www.heliusmedical.com.

About the PoNS™ Device and PoNS Treatment™

The Portable Neuromodulation Stimulator (PoNS) is an authorized class II, non-implantable medical device authorized for sale in Canada. PoNS is intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy and indicated as a short term treatment (14 weeks) chronic balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with physical therapy. The PoNS is an investigational medical device in the United States, the European Union, and Australia, and is currently under review for clearance by the AUS Therapeutic Goods Administration. PoNS Treatment is currently not commercially available in the United States, the European Union or Australia.

Investor Relations Contact:

Westwicke Partners on behalf of Helius Medical Technologies, Inc.

Mike Piccinino, CFA

investorrelations@heliusmedical.com

FAQ

What is the date of HSDT's presentation at the Virtual Summer Summit?

HSDT's presentation at the Virtual Summer Summit is scheduled for June 9th, 2020, at 4:30 p.m. Eastern Time.

How can I access the webcast of HSDT's presentation?

You can access the live audio webcast of HSDT's presentation under the 'Events' section of their investor relations website.

What is the focus of Helius Medical Technologies (HSDT)?

Helius Medical Technologies (HSDT) focuses on neurological wellness and develops non-invasive technologies for brain health.

What is the Portable Neuromodulation Stimulator (PoNS™) used for?

The PoNS™ device is intended for short-term treatment of gait deficits due to mild and moderate symptoms from multiple sclerosis and chronic balance deficits from traumatic brain injury.

Is the PoNS device available in the United States?

The PoNS device is currently an investigational medical device in the United States and is not commercially available there.